Cannabis Approval Status for PTSD and Anxiety

Critical Distinction: State Programs vs. FDA Approval

Medical marijuana itself has never received FDA approval for any medical indication whatsoever, despite legalization in numerous state medical cannabis programs 1, 2
Cannabis remains federally classified as a Schedule I controlled substance, defined as having "no currently accepted medical use" and "high potential for misuse" 1, 2
The only FDA-approved cannabinoid medications are Epidiolex (CBD) for rare epilepsy syndromes, and dronabinol/nabilone (synthetic THC) for chemotherapy-induced nausea and AIDS-related anorexia—none are approved for PTSD or anxiety 1, 2

As of 2017, 25 states plus DC, Guam, and Puerto Rico had comprehensive medical marijuana programs, with individual states determining their own qualifying conditions 3
In North Dakota specifically, possession of less than half an ounce carries a maximum $1000 fine (decriminalization status), but this does not constitute medical approval 4
State medical marijuana programs operate independently of FDA approval processes and do not represent evidence-based medical endorsement 1, 2

Cannabis can paradoxically cause or exacerbate anxiety disorders rather than improve them, particularly in vulnerable populations 1
Older adults using cannabis face higher risk for behavioral health issues including anxiety and depression, plus sedation, obtundation, and myocardial ischemia 1

Pregnant and breastfeeding individuals must avoid all cannabis products due to fetal brain development risks and increased premature birth risk 1, 2
Adolescents face elevated risks including neurodevelopmental decline, psychotic disorders, depression, and suicidal ideation with cannabis use 1, 2
Elderly patients (≥65 years) are at higher risk for behavioral health issues, sedation, and cardiovascular events 1, 2